Toggle SGML Header (+)


Section 1: 8-K (8-K)

8-K

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

 

FORM 8-K

 

 

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported):    October 5, 2017

Commission File Number: 0-24260

 

 

 

LOGO

Amedisys, Inc.

(Exact name of registrant as specified in charter)

 

 

 

Delaware   11-3131700
(State or other jurisdiction   (IRS Employer
of incorporation)   Identification No.)

3854 American Way, Suite A, Baton Rouge, LA 70816

(Address of principal executive offices, including zip code)

(225) 292-2031 or (800) 467-2662

(Registrant’s telephone number, including area code)

Not Applicable

(Former name or former address, if changed since last report)

 

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2 below):

 

Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company    ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.    ☐

 

 

 


Item 5.02. Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On October 5, 2017, Gary Willis resigned as the Chief Financial Officer of Amedisys, Inc. (the “Company”) and accepted an Executive Vice President and Chief Financial Officer position with another healthcare company.

On October 5, 2017, the Board of Directors of the Company appointed Scott G. Ginn, currently the Company’s Chief Accounting Officer, as the Company’s Chief Financial Officer, effective immediately. Mr. Ginn, age 48, has served as the Company’s Chief Accounting Officer since February 2017. He previously served as the Company’s Senior Vice President of Finance and Accounting from October 2015 to February 2017 and Senior Vice President of Accounting and Controller from April 2007 to October 2015. Prior to joining the Company, he was a Director at Postlethwaite & Netterville, a professional accounting corporation. Mr. Ginn is a Certified Public Accountant.

Mr. Ginn will participate in the Amedisys Holding, L.L.C. Severance Plan for Key Executives dated April 30, 2015, as amended. Mr. Ginn does not have a family relationship with any of the current officers or directors of the Company. There is no currently proposed transaction, and since the beginning of fiscal year 2016 there has not been any transaction, involving the Company and Mr. Ginn which was a related person transaction within the meaning of Item 404(a) of Regulation S-K.

 

Item 7.01. Regulation FD Disclosure.

On October 6, 2017, the Company issued a press release announcing the resignation of Mr. Willis and the appointment of Mr. Ginn as the Company’s Chief Financial Officer, a copy of which is furnished herewith as Exhibit 99.1 to this Current Report on Form 8-K.

The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) is being “furnished” and shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of Section 18, nor shall it be incorporated by reference into a filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing. The information included in this Current Report on Form 8-K under this Item 7.01 (including Exhibit 99.1 hereto) will not be deemed an admission as to the materiality of any information required to be disclosed solely to satisfy the requirements of Regulation FD.

 

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

 

Exhibit
Number

  

Description

99.1    Press Release dated October 6, 2017


SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

AMEDISYS, INC.

By:   /s/ Paul B. Kusserow
 

Paul B. Kusserow

 

President and Chief Executive Officer

DATE: October 6, 2017

(Back To Top)

Section 2: EX-99.1 (EX-99.1)

EX-99.1

Exhibit 99.1

 

LOGO    

Contact:

Kendra Kimmons

Vice President of Marketing & Communications

225-299-3708

kendra.kimmons@amedisys.com

Scott Ginn Promoted to Chief Financial Officer at Amedisys

BATON ROUGE, La., October 6, 2017 – Amedisys, Inc. (NASDAQ:AMED), a leading home health, hospice and personal care company, today announces the promotion of Scott Ginn to Chief Financial Officer, effective immediately. Gary D. Willis has resigned his position as CFO and accepted an executive vice president and CFO position with another healthcare company.

“I am really delighted to make this announcement. Scott recently served as our Chief Accounting Officer, and was responsible for all of our accounting operations, cost control systems and financial reporting,” said President and CEO Paul Kusserow. “During his more than ten years with Amedisys, he has made many significant contributions to the Company as Senior Vice President of Accounting and Controller and Senior Vice President of Finance and Accounting. He has played a pivotal role in leading financial operations and building strong relationships with our analysts, lenders and shareholders.”

In his leadership roles at Amedisys, Ginn has been responsible for all accounting functions including SEC reporting, payroll, budgeting and tax. Ginn has also successfully led the internal audit, SOX and risk management departments.

“When I first came to Amedisys, it was my goal to one day serve as its CFO,” stated Ginn. “It has been an exciting journey to be a part of the financial team that helped to grow our Company from a $500 million organization to $1.5 billion. I am committed to Amedisys and am excited to help achieve our growth strategies to allow us to take care of even more patients in the home.”

“Given Scott’s comprehensive experience; his leadership and teambuilding skills; decade of service with Amedisys; and deep knowledge of our three lines of business, he is the ideal successor as our Chief Financial Officer,” stated Kusserow. “Scott’s knowledge of our industry is unmatched.”

Prior to Amedisys, Ginn served as a Director at Postlethwaite & Netterville, a professional accounting and business advisory firm. He is a Certified Public Accountant and earned his bachelor’s degree in accounting from Louisiana State University.

About Amedisys:

Amedisys, Inc. is a leading healthcare at home Company delivering personalized home health, hospice and personal care. Amedisys is focused on delivering the care that is best for our patients, whether that is home-based personal care; recovery and rehabilitation after an operation or injury; care focused on empowering them to manage a chronic disease; or hospice care at the end of life. More than 2,200 hospitals and 61,900 physicians nationwide have chosen Amedisys as a partner in post-acute care. Founded in 1982, headquartered in Baton Rouge, LA with an executive office in Nashville, TN, Amedisys is a publicly held company. With more than 16,000 employees, in 432 care centers in 34 states, Amedisys is dedicated to delivering the highest quality of care to the doorsteps of more than 385,000 patients in need every year. For more information about the Company, please visit: www.amedisys.com.

#     #     #

(Back To Top)